Completed NA INTERVENTIONAL NCT00205231

A Pilot Study to Examine the Feasibility and Effect of Tumor Necrosis Factor (TNF) Inhibition on HIV Disease

A Pilot Study to Examine the Feasibility and Effect on Tumor Necrosis Factor (TNF) Inhibition on HIV Disease

Sponsor: Immunex Corporation

Interventions etanercept

Updated 7 times since 2017 Last updated: Mar 20, 2019 Started: May 31, 2002 Primary completion: May 1, 2004 Completion: May 1, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on HIV Infections, this trial is completed. The trial is conducted by Immunex Corporation and has accumulated 7 data snapshots since 2002. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Apr 2019 — Jan 2021 [monthly]

Completed NA
Jun 2018 — Apr 2019 [monthly]

Completed NA

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed NA
Jan 2017 — Feb 2017 [monthly]

Completed NA

First recorded

May 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Immunex Corporation
University of Wisconsin, Madison

Data source: University of Wisconsin, Madison

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Madison, United States